Last 7 days
0.3%
Last 30 days
8.9%
Last 90 days
12.7%
Trailing 12 Months
84.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-09-06 | SHERMAN JEFFREY W | gifted | - | - | -2,165 | evp and chief medical officer |
2023-05-09 | Himawan Jeff | gifted | - | - | 7,873 | - |
2023-05-09 | Himawan Jeff | gifted | - | - | -7,873 | - |
2023-04-28 | Watkins Thomas | acquired | - | - | 3,913 | - |
2023-04-28 | Witz Pascale | acquired | - | - | 3,913 | - |
2023-04-28 | Witz Pascale | sold (taxes) | -208,870 | 111 | -1,879 | - |
2023-04-28 | Shannon James Samuel | acquired | - | - | 3,913 | - |
2023-04-28 | Daniel William F | sold (taxes) | -208,870 | 111 | -1,879 | - |
2023-04-28 | Mahony Susan | sold (taxes) | -208,870 | 111 | -1,879 | - |
2023-04-28 | Himawan Jeff | acquired | - | - | 3,913 | - |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | added | 3,462 | 14,148,400 | 14,679,400 | 0.12% |
2023-09-20 | BARCLAYS PLC | reduced | -36.71 | -68,159,000 | 100,710,000 | 0.06% |
2023-09-12 | Farther Finance Advisors, LLC | reduced | -0.1 | -6,575 | 105,730 | 0.02% |
2023-09-11 | BLUEFIN CAPITAL MANAGEMENT, LLC | new | - | 5,921,790 | 5,921,790 | 1.13% |
2023-08-23 | Stonebridge Capital Advisors LLC | unchanged | - | -314 | 5,143 | -% |
2023-08-23 | CTC Alternative Strategies, Ltd. | new | - | 638,699 | 638,699 | 0.80% |
2023-08-22 | COMERICA BANK | new | - | 90,000 | 90,000 | 0.01% |
2023-08-22 | Asset Dedication, LLC | unchanged | - | - | 1,000 | -% |
2023-08-21 | Affinity Asset Advisors, LLC | sold off | -100 | -2,182,800 | - | -% |
2023-08-21 | VisionPoint Advisory Group, LLC | new | - | 41,140 | 41,140 | 0.02% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 9.37% | 21,236,103 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 07, 2023 | blackrock inc. | 6.5% | 14,794,254 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 5.7% | 13,008,024 | SC 13G/A | |
Feb 11, 2021 | renaissance technologies llc | 3.08% | 6,798,963 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 9.03% | 19,920,258 | SC 13G/A | |
Feb 08, 2021 | fmr llc | - | 0 | SC 13G | |
Jan 29, 2021 | blackrock inc. | 6.4% | 14,206,978 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 9.12% | 17,089,414 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 12, 2023 | 8-K | Current Report | |
Sep 07, 2023 | 4 | Insider Trading | |
Sep 05, 2023 | 8-K | Current Report | |
Sep 01, 2023 | 8-K | Current Report | |
Aug 08, 2023 | 10-Q | Quarterly Report | |
Aug 08, 2023 | 8-K | Current Report | |
Jul 28, 2023 | 4 | Insider Trading | |
Jul 28, 2023 | 4 | Insider Trading | |
Jul 28, 2023 | 4 | Insider Trading | |
Jul 28, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
LLY | 495.3B | 29.5B | -0.51% | 77.59% | 76.23 | 16.78 | 1.53% | 14.16% |
JNJ | 417.0B | 97.8B | -1.74% | -2.10% | 31.95 | 4.27 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -4.46% | 23.17% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 184.6B | 77.9B | -10.83% | -26.03% | 8.6 | 2.37 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -4.32% | -16.75% | 23.72 | 3.25 | -4.15% | 20.34% |
MID-CAP | ||||||||
RETA | 6.5B | - | 1.87% | 616.21% | -74.09 | 4.1K | -86.94% | 71.24% |
PRGO | 4.4B | 4.6B | -14.86% | -16.47% | -64.45 | 0.94 | 6.60% | 42.04% |
SMALL-CAP | ||||||||
TLRY | 1.6B | 627.1M | -7.75% | -14.29% | -1.08 | 2.51 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -12.24% | -14.48% | 35.26 | 2.41 | 0.62% | -24.59% |
INVA | 841.4M | 244.3M | -2.86% | 8.68% | 4.27 | 3.44 | -39.50% | -4.99% |
CRON | 792.7M | 109.5M | 17.51% | -27.27% | -5.52 | 7.24 | -2.66% | -32.13% |
ACRS | 470.6M | 31.2M | -8.53% | -51.99% | -4.47 | 15.1 | 407.54% | -26.47% |
CGC | 462.3M | 453.3M | 100.98% | -69.12% | -0.38 | 1.02 | -16.04% | 55.90% |
OCUL | 252.8M | 54.6M | -17.14% | -44.23% | -2.79 | 4.63 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
41.9%
29.0%
43.8%
13.9%
50.4%
37.3%
14.2%
Y-axis is the maximum loss one would have experienced if Horizon Pharma was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | 1.9% | 3,644 | 3,576 | 3,629 | 3,701 | 3,813 | 3,769 | 3,226 | 2,957 | 2,557 | 2,187 | 2,200 | 1,819 | 1,518 | 1,376 | 1,300 | 1,292 | 1,282 | 1,264 | 1,208 | 1,126 | 1,073 |
Gross Profit | 3.0% | 2,741 | 2,662 | 2,709 | 2,781 | 2,875 | 2,860 | 2,432 | 2,242 | 1,942 | 1,651 | 1,668 | 1,353 | 1,114 | 1,004 | 938 | 926 | 915 | 895 | 816 | 690 | 602 |
Operating Expenses | 1.1% | 2,228 | 2,203 | 2,091 | 2,104 | 2,027 | 1,963 | 1,889 | 1,692 | 1,494 | 1,305 | 1,178 | 1,049 | 989 | 892 | 811 | 772 | 747 | 741 | 778 | 802 | 802 |
S&GA Expenses | 2.2% | 1,658 | 1,622 | 1,541 | 1,567 | 1,530 | 1,487 | 1,446 | 1,324 | 1,190 | 1,057 | 973 | 882 | 828 | 773 | 697 | 686 | 676 | 685 | 692 | 685 | 678 |
R&D Expenses | 10.0% | 516 | 469 | 438 | 422 | 397 | 434 | 345 | 278 | 218 | 159 | 129 | 167 | 161 | 109 | 103 | 94.00 | 91.00 | 87.00 | 83.00 | 94.00 | 91.00 |
EBITDA | -100.0% | - | 885 | 1,024 | 1,064 | 1,223 | 917 | 736 | 559 | 465 | 492 | 621 | 414 | 180 | 149 | 130 | - | - | - | - | - | - |
EBITDA Margin | -100.0% | - | 0.25* | 0.28* | 0.29* | 0.32* | 0.24* | 0.23* | 0.19* | 0.18* | 0.22* | 0.28* | 0.23* | 0.12* | 0.11* | 0.10* | - | - | - | - | - | - |
Interest Expenses | 14.2% | 139 | 122 | 106 | 92.00 | 84.00 | 83.00 | 74.00 | 65.00 | 54.00 | 44.00 | 52.00 | 55.00 | 59.00 | 89.00 | 78.00 | 117 | 106 | 113 | 112 | 107 | 111 |
Earnings Before Taxes | 18.9% | 444 | 373 | 527 | 584 | 756 | 807 | 463 | 481 | 376 | 263 | 402 | 209 | -5.11 | -18.06 | -20.22 | -4.51 | 40.00 | 30.00 | -83.13 | -234 | -323 |
EBT Margin | -100.0% | - | 0.10* | 0.15* | 0.16* | 0.20* | 0.21* | 0.14* | 0.16* | 0.15* | 0.12* | 0.18* | 0.11* | 0.00* | -0.01* | -0.02* | - | - | - | - | - | - |
Net Income | 17.8% | 438 | 372 | 521 | 574 | 765 | 862 | 534 | 552 | 518 | 280 | 390 | 792 | 517 | 592 | 573 | 82.00 | 97.00 | 77.00 | -38.38 | -178 | -275 |
Net Income Margin | -100.0% | - | 0.10* | 0.14* | 0.16* | 0.20* | 0.23* | 0.17* | 0.19* | 0.20* | 0.13* | 0.18* | 0.44* | 0.34* | 0.43* | 0.44* | - | - | - | - | - | - |
Free Cashflow | -100.0% | - | 1,054 | 1,194 | 1,314 | 1,346 | 1,182 | 959 | 810 | 522 | 545 | 386 | 197 | 185 | 173 | 408 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | 3.4% | 9,299 | 8,993 | 9,115 | 9,028 | 8,853 | 8,740 | 8,678 | 8,609 | 8,207 | 7,847 | 6,073 | 5,767 | 4,538 | 4,315 | 4,436 | 3,721 | 3,708 | 3,936 | 3,942 | 4,019 | 3,990 |
Current Assets | 8.9% | 3,922 | 3,603 | 3,653 | 3,412 | 3,203 | 2,948 | 2,800 | 2,414 | 2,175 | 1,831 | 3,070 | 2,732 | 1,489 | 1,414 | 1,686 | 1,479 | 1,402 | 1,560 | 1,546 | 1,339 | 1,235 |
Cash Equivalents | 6.6% | 2,465 | 2,312 | 2,353 | 2,131 | 1,893 | 1,643 | 1,580 | 1,069 | 812 | 812 | 2,080 | 1,725 | 718 | 755 | 1,076 | 884 | 866 | 1,033 | 959 | 807 | 710 |
Inventory | 3.5% | 170 | 164 | 170 | 190 | 204 | 227 | 152 | 237 | 259 | 238 | 75.00 | 77.00 | 66.00 | 68.00 | 54.00 | 59.00 | 51.00 | 52.00 | 51.00 | 53.00 | 50.00 |
Net PPE | 1.8% | 362 | 356 | 341 | 318 | 302 | 295 | 292 | 286 | 220 | 202 | 189 | 156 | 139 | 142 | 30.00 | 26.00 | 25.00 | 22.00 | 20.00 | 17.00 | 18.00 |
Goodwill | 0% | 1,011 | 1,011 | 1,011 | 1,011 | 1,011 | 1,067 | 1,067 | 1,069 | 1,069 | 663 | 414 | 414 | 414 | 414 | 414 | 414 | 414 | 414 | 414 | 426 | 426 |
Current Liabilities | 3.7% | 918 | 885 | 949 | 861 | 791 | 825 | 887 | 854 | 853 | 774 | 876 | 784 | 985 | 592 | 723 | 636 | 637 | 895 | 709 | 692 | 726 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 250 | - | - | - |
Shareholder's Equity | 4.2% | 5,311 | 5,096 | 5,072 | 5,034 | 4,946 | 4,818 | 4,672 | 4,450 | 4,074 | 3,855 | 4,025 | 3,797 | 2,362 | 2,188 | 2,185 | 1,556 | 1,521 | 1,504 | 1,190 | 1,051 | 987 |
Retained Earnings | 19.7% | 772 | 645 | 590 | 606 | 584 | 523 | 319 | 145 | -181 | -339 | -215 | -406 | -699 | -619 | -605 | -1,198 | -1,216 | -1,211 | -1,178 | -1,414 | -1,440 |
Additional Paid-In Capital | 1.6% | 4,522 | 4,449 | 4,474 | 4,425 | 4,381 | 4,315 | 4,373 | 4,311 | 4,260 | 4,200 | 4,246 | 4,209 | 3,068 | 2,814 | 2,798 | 2,761 | 2,744 | 2,722 | 2,375 | 2,338 | 2,307 |
Shares Outstanding | 0.2% | 229 | 229 | 227 | 229 | 230 | 229 | 227 | 226 | 225 | 224 | 221 | 212 | 193 | 190 | 188 | 186 | 185 | 173 | 169 | 167 | 165 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | -7.8% | 1,041 | 1,128 | 1,258 | 1,370 | 1,415 | 1,255 | 1,035 | 907 | 604 | 615 | 556 | 337 | 316 | 308 | 426 | 344 | 341 | 312 | 195 | 229 | 213 |
Share Based Compensation | 7.8% | 208 | 193 | 182 | 186 | 196 | 205 | 219 | 203 | 179 | 151 | 147 | 138 | 126 | 120 | 91.00 | 95.00 | 105 | 115 | 115 | 121 | 126 |
Cashflow From Investing | -5.8% | -142 | -135 | -134 | -121 | -231 | -305 | -2,994 | -3,022 | -2,902 | -2,975 | -464 | -411 | -393 | -234 | -17.86 | 26.00 | 40.00 | 38.00 | 28.00 | -1.87 | -13.54 |
Cashflow From Financing | -2.6% | -334 | -326 | -347 | -177 | -91.16 | -109 | 1,470 | 1,465 | 2,392 | 2,413 | 905 | 913 | -70.57 | -350 | -290 | -293 | -227 | 9.00 | -16.60 | -45.53 | -46.09 |
Buy Backs | - | - | - | 250 | 454 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) - USD ($) | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Income Statement [Abstract] | ||||
Net sales | $ 944,959,000 | $ 876,411,000 | $ 1,777,018,000 | $ 1,761,656,000 |
Cost of goods sold | 219,958,000 | 230,216,000 | 428,521,000 | 445,278,000 |
Gross profit | 725,001,000 | 646,195,000 | 1,348,497,000 | 1,316,378,000 |
OPERATING EXPENSES: | ||||
Research and development | 150,035,000 | 103,246,000 | 284,183,000 | 206,378,000 |
Selling, general and administrative | 434,125,000 | 398,221,000 | 887,479,000 | 770,955,000 |
Impairment of goodwill | 0 | 56,171,000 | 0 | 56,171,000 |
Gain on sale of asset | (2,000,000) | (2,000,000) | ||
Total operating expenses | 582,160,000 | 557,638,000 | 1,169,662,000 | 1,033,504,000 |
Operating income | 142,841,000 | 88,557,000 | 178,835,000 | 282,874,000 |
OTHER EXPENSE, NET: | ||||
Interest expense, net | (12,098,000) | (21,409,000) | (27,638,000) | (42,665,000) |
Foreign exchange gain | 326,000 | 28,000 | 417,000 | 448,000 |
Other income (expense), net | 4,183,000 | (2,389,000) | 2,840,000 | (3,131,000) |
Total other expense, net | (7,589,000) | (23,770,000) | (24,381,000) | (45,348,000) |
Income before expense (benefit) for income taxes | 135,252,000 | 64,787,000 | 154,454,000 | 237,526,000 |
Expense (benefit) for income taxes | 8,181,000 | 3,813,000 | (27,301,000) | (27,709,000) |
Net income | $ 127,071,000 | $ 60,974,000 | $ 181,755,000 | $ 265,235,000 |
Net income per ordinary share—basic | $ 0.56 | $ 0.27 | $ 0.80 | $ 1.16 |
Weighted average ordinary shares outstanding—basic | 228,743,143 | 230,020,004 | 228,571,356 | 229,559,715 |
Net income per ordinary share—diluted | $ 0.54 | $ 0.26 | $ 0.78 | $ 1.12 |
Weighted average ordinary shares outstanding—diluted | 233,935,591 | 236,166,384 | 233,938,149 | 236,077,147 |
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX | ||||
Foreign currency translation adjustments | $ 1,409,000 | $ (1,433,000) | $ 794,000 | $ (1,893,000) |
Pension and other post-employment benefit plan remeasurements | 179,000 | (547,000) | 2,003,000 | (222,000) |
Interest rate swap contracts designated as cash flow hedges | 13,339,000 | 2,011,000 | 6,287,000 | 2,011,000 |
Other comprehensive income (loss) | 14,927,000 | 31,000 | 9,084,000 | (104,000) |
Comprehensive income | $ 141,998,000 | $ 61,005,000 | $ 190,839,000 | $ 265,131,000 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 2,464,623 | $ 2,352,833 |
Restricted cash | 4,791 | 4,755 |
Accounts receivable, net | 717,417 | 676,347 |
Inventories, net | 170,325 | 169,559 |
Prepaid expenses and other current assets | 564,808 | 449,349 |
Total current assets | 3,921,964 | 3,652,843 |
Property, plant and equipment, net | 362,326 | 340,509 |
Developed technology and other intangible assets, net | 2,486,565 | 2,664,777 |
In-process research and development | 810,000 | 810,000 |
Goodwill | 1,010,538 | 1,010,538 |
Deferred tax assets, net | 444,306 | 431,814 |
Other long-term assets | 263,042 | 204,135 |
Total assets | 9,298,741 | 9,114,616 |
CURRENT LIABILITIES: | ||
Accounts payable | 85,543 | 155,800 |
Accrued expenses and other current liabilities | 496,669 | 457,557 |
Accrued trade discounts and rebates | 319,469 | 319,780 |
Long-term debt-current portion | 16,000 | 16,000 |
Total current liabilities | 917,681 | 949,137 |
LONG-TERM LIABILITIES: | ||
Long-term debt, net | 2,541,458 | 2,546,837 |
Deferred tax liabilities, net | 264,815 | 342,017 |
Other long-term liabilities | 263,828 | 204,451 |
Total long-term liabilities | 3,070,101 | 3,093,305 |
COMMITMENTS AND CONTINGENCIES | ||
SHAREHOLDERS’ EQUITY: | ||
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2023 and December 31, 2022; 229,323,393 and 227,625,913 shares issued at June 30, 2023 and December 31, 2022, respectively; and 228,939,027 and 227,241,547 shares outstanding at June 30, 2023 and December 31, 2022, respectively | 23 | 23 |
Treasury stock, 384,366 ordinary shares at June 30, 2023 and December 31, 2022 | (4,585) | (4,585) |
Additional paid-in capital | 4,522,145 | 4,474,199 |
Accumulated other comprehensive income | 21,612 | 12,528 |
Retained earnings | 771,764 | 590,009 |
Total shareholders’ equity | 5,310,959 | 5,072,174 |
Total liabilities and shareholders' equity | $ 9,298,741 | $ 9,114,616 |